Welcome to our dedicated page for PELI news (Ticker: PELI), a resource for investors and traders seeking the latest updates and insights on PELI stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PELI's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PELI's position in the market.
Pelican Acquisition Corporation (NASDAQ: PELIU) has announced the pricing of its initial public offering (IPO) at $10.00 per unit, aiming to raise $75 million through the sale of 7.5 million units. Each unit comprises one ordinary share and one right, with the right convertible to one-tenth of an ordinary share upon completing an initial business combination.
Trading commenced on May 23, 2025 on the Nasdaq Global Market under "PELIU". The ordinary shares and rights will later trade separately under "PELI" and "PELIR". EarlyBirdCapital serves as the sole book-runner, with IB Capital as co-manager. The underwriters have a 45-day option to purchase up to 1.125 million additional units for over-allotments. The offering is expected to close on May 27, 2025.
